Figure 3.

PET imaging of GRP78 overexpression in pancreatic cancer xenograft model. (A) PET images were decay corrected, with 3 time points shown at 1, 17, and 48 h postinjection of ⁶⁴Cu-DOTA-MAb159 (targeting GRP78) or ⁶⁴Cu-DOTA-IgG (control). (B) Biodistribution of ⁶⁴Cu-DOTA-MAb159 and ⁶⁴Cu-DOTA-IgG, through direct tissue sampling, at 48 h postinjection. (C) PET quantification of ⁶⁴Cu-DOTA-MAb159 and ⁶⁴Cu-DOTA-IgG in major organs at three imaging time points (1, 17, and 48 h). Reprinted with permission from ref (49). Copyright 2015 Society of Nuclear Medicine and Molecular Imagining, Inc.